CTOs on the Move

Chugai Pharma

www.chugai-pharm.com

 
Chugai Pharma USA (CPUSA), a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd.(Chugai) located in Berkeley Heights NJ, is focused on early stage clinical research, mainly in the disease areas of oncology, renal disease, and bone and joint disease. CPUSA operates as part of Chugai`s Translational Clinical Research Division (TCRD), a global function with offices in Europe, Japan and the U.S. TCRD is dedicated to late pre-clinical and early clinical development of Chugai-originated pipeline products. TCRD aims to accelerate the proof-of-concept process by bringing translational research-powered medicines to global development stage and ultimately to market, as efficiently ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.chugai-pharm.com
  • 300 Connell Drive Suite 3100
    Berkeley Heights, NJ USA 07922
  • Phone: 908.516.1350

Executives

Name Title Contact Details

Similar Companies

TotalAncillary

Comprehensive Solution for Revenue Generating Medical Ancillary Services

FOCUS Pharmaceuticals

FOCUS Pharmaceuticals is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

QRxPharma Limited

QRxPharma Limited is a Bedminster, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cyteir

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.

Connections Behavior Planning & Intervention

ABA Therapy for children with ASD, EBD, & developmental disabilities. We serve King County, WA including Kent, Renton, Seattle, Kirkland, Redmond, & more.